News
Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...
Investments in San Diego County startups decreased by 35% in the second quarter compared to a year ago, marking it the third ...
StockStory.org on MSN3d
Gilead Sciences’s Q2 Earnings Call: Our Top 5 Analyst Questions
Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and ...
Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly ...
For anyone who wants to understand Gilead Sciences' profit beyond the statutory numbers, it's important to note that during ...
U.S. stocks are drifting near their record heights as Wall Street waits for an upcoming update on inflation.
Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.
2d
Zacks Investment Research on MSNIs Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...
Legend Biotech announced its Q2 earnings, reporting $439m of revenues for its only commercial product, the cell therapy ...
Wall Street and the Fed will get more insight next week on inflation’s temperature and the economy. The government will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results